

Editorial

Open Access



## Editorial - Reflecting on three years of *M&TOD* - Where we are and where we are going

Amedeo Lonardo 

Modena University Hospital Trust (-2023), Modena 41126, Italy.

**Correspondence to:** Prof. Amedeo Lonardo, Founding Editor and Editor-in-Chief of *Metabolism and Target Organ Damage*, Modena 41126, Italy. E-mail: a.lonardo@libero.it

**How to cite this article:** Lonardo A. Editorial - Reflecting on three years of *M&TOD* - Where we are and where we are going. *Metab Target Organ Damage* 2024;4:27. <https://dx.doi.org/10.20517/mtod.2024.65>

**Received:** 31 Jul 2024 **Accepted:** 6 Aug 2024 **Published:** 14 Aug 2024

**Academic Editor:** Juan Pablo Arab **Copy Editor:** Dong-Li Li **Production Editor:** Dong-Li Li

Three years ago, the launch of our inaugural editorial<sup>[1]</sup> and the original artwork inspired by a picture of Norwegian painter Edvard Munch [Figure 1] marked the beginning of the novel journal “*Metabolism and Target Organ Damage*” (*M&TOD*). At that time, with the ongoing COVID-19 pandemic and numerous competing editorial initiatives, the future of *M&TOD* seemed uncertain.


Today, as of July 2024, we can proudly say that *M&TOD* has established itself as a successful biomedical journal with a global membership, authorship, and readership. With 77 published articles and 236 citations (80 of which have been received this year alone), our journal has gained an impressive 3.0 citation score. This accomplishment reflects the tremendous effort of everyone involved and validates our hopes for further progress in the near future. My sincere thanks to you all! Without your invaluable contributions, these achievements would not have been possible.

Thanks to our Honorary Editors-in-Chief, Professors Giovanni Targher and Christopher Byrne. Thanks to the 53 Editorial Board members from 10 different countries, and to the 43 Junior Editorial Board members. Thanks to the Guest Editors of our three completed Special Issues and the 25 ongoing Special Issues. Thanks to our 226 reviewers, whose voluntary support has contributed in a determinant manner to our journal’s elevated scientific ranking. Thanks to all our 320 authors from Northern and Southern America, Europe, Asia, Australia and Africa, whose worldwide prestige has shaped the history and current state of



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.





**Figure 1.** Cover of the first issue of *M&TOD*. *M&TOD: Metabolism and Target Organ*.

MASLD research. Their excellent work has been crucial to *M&TOD*'s success. Thanks to all the colleagues involved in our Webinars and Interviews, which have generated substantial interest.

Special thanks to the Editorial Office, particularly Alani and Jennifer, together with their colleagues, whose kindness, efficiency, and professionalism have been instrumental in maintaining communication with our extensive network of colleagues - including Editorial Board members, authors, reviewers, lecturers, and interviewees. The Editorial Office has also efficiently relayed suggestions to the Technical Office, ensuring that our journal's graphical format remains up-to-date with the evolving needs of a growing publication.

In my inaugural editorial<sup>[1]</sup>, I concluded with the following statement: "The Editorial Board of this journal is committed to working hard to guarantee accurate and fair evaluation and prompt publication of papers received, with the aim of creating a scientifically solid and successful scientific journal." I am proud to say that we have fully honored this commitment. The remarkable achievements noted above represent just a fraction of *M&TOD*'s exciting progress, as detailed in our recent journal activities analysis<sup>[2]</sup>. I am also proud to mention that I have had the honor of co-authoring 7 of the 10 most cited articles<sup>[3-9]</sup>.

These attainments clearly demonstrate that everyone involved in running this journal has not only diligently fulfilled their responsibilities but has also exceeded them with dedication and passion for the journal! Therefore, we are now well-positioned to apply for inclusion in the PubMed database at the earliest

favorable opportunity. To this end, we remain dedicated to continuously improving the quality of the papers we publish, with the goal of ultimately increasing citation rates.

In an era when research independence and freedom may face potential threats, our journal remains steadfast in ensuring autonomy and meritocracy for all researchers who, in various capacities, are involved in *M&TOD*. We welcome scholars from around the world who wish to collaborate with us to achieve excellence in publishing, which is the core mission of our loved journal.

## DECLARATIONS

### Authors' contributions

The author contributed solely to the article.

### Availability of data and materials

Not applicable.

### Financial support and sponsorship

None.

### Conflicts of interest

Lonardo A is the Founding Editor and Editor-in-Chief of the journal *Metabolism and Target Organ Damage*. However, he was not involved in any phase of the Editorial handling of this manuscript.

### Ethical approval and consent to participate

Not applicable.

### Consent for publication

Not applicable.

### Copyright

© The Author(s) 2024.

## REFERENCES

1. Lonardo A. Editorial: metabolism and target organ damage. *Metab Target Organ Damage* 2021;1:1. DOI
2. 2024 Semi-annual Publication Report. Available from: <https://i.oaes.cc/uploads/20240814/84f4582eb0b743228c553e9b83c2255f.pdf>. [Last accessed on 14 Aug 2024].
3. Ballestri S, Mantovani A, Byrne CD, Lonardo A, Targher G. Diagnostic accuracy of ultrasonography for the detection of hepatic steatosis: an updated meta-analysis of observational studies. *Metab Target Organ Damage* 2021;1:7. DOI
4. Lonardo A, Singal AK, Osna N, Kharbanda KK. Effect of cofactors on NAFLD/NASH and MAFLD. A paradigm illustrating the pathomechanics of organ dysfunction. *Metab Target Organ Damage* 2022;2:12. DOI PubMed PMC
5. Lonardo A, Ballestri S, Bedogni G, Bellentani S, Tiribelli C. The Fatty liver Index (FLI) 15 years later: a reappraisal. *Metab Target Organ Damage* 2021;1:10. DOI
6. Lonardo A, Byrne CD, Targher G. Precision medicine approaches in metabolic disorders and target organ damage: where are we now, and where are we going? *Metab Target Organ Damage* 2021;1:3. DOI
7. Ballestri S, Mantovani A, Girolamo MD, Baldelli E, Capitelli M, Lonardo A. Liver fibrosis in nonalcoholic fatty liver disease patients: noninvasive evaluation and correlation with cardiovascular disease and mortality. *Metab Target Organ Damage* 2023;3:1. DOI
8. Lonardo A, Ndrepepa G. Concise review: gamma-glutamyl transferase - evolution from an indiscriminate liver test to a biomarker of cardiometabolic risk. *Metab Target Organ Damage* 2022;2:17. DOI
9. Lugari S, Baldelli E, Lonardo A. Metabolic primary liver cancer in adults: risk factors and pathogenic mechanisms. *Metab Target Organ Damage* 2023;3:5. DOI